436 related articles for article (PubMed ID: 28115678)
1. Elimination of Kala-Azar from the Southeast Asia Region.
Bhattacharya SK; Dash AP
Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
[TBL] [Abstract][Full Text] [Related]
2. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
3. Insecticide resistance in phlebotomine sandflies in Southeast Asia with emphasis on the Indian subcontinent.
Dhiman RC; Yadav RS
Infect Dis Poverty; 2016 Nov; 5(1):106. PubMed ID: 27817749
[TBL] [Abstract][Full Text] [Related]
4. Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment.
Sundar S; Mondal D; Rijal S; Bhattacharya S; Ghalib H; Kroeger A; Boelaert M; Desjeux P; Richter-Airijoki H; Harms G
Trop Med Int Health; 2008 Jan; 13(1):2-5. PubMed ID: 18290995
[No Abstract] [Full Text] [Related]
5. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
Gurunath U; Joshi R; Agrawal A; Shah V
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
[TBL] [Abstract][Full Text] [Related]
6. Implication of vector characteristics of Phlebotomus argentipes in the kala-azar elimination programme in the Indian sub-continent.
Chowdhury R; Kumar V; Mondal D; Das ML; Das P; Dash AP; Kroeger A
Pathog Glob Health; 2016 May; 110(3):87-96. PubMed ID: 27376500
[TBL] [Abstract][Full Text] [Related]
7. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
8. Can visceral leishmaniasis be eliminated from Asia?
Joshi A; Narain JP; Prasittisuk C; Bhatia R; Hashim G; Jorge A; Banjara M; Kroeger A
J Vector Borne Dis; 2008 Jun; 45(2):105-11. PubMed ID: 18592839
[TBL] [Abstract][Full Text] [Related]
9. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
10. A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K; Pal B; Siddiqui NA; Lal CS; Ali V; Bimal S; Kumar A; Verma N; Das VNR; Singh SK; Topno RK; Das P
Indian J Dermatol Venereol Leprol; 2021; 87(1):34-41. PubMed ID: 33580944
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the diagnosis and treatment of kala-azar.
Sundar S; Chakravarty J
Natl Med J India; 2012; 25(2):85-9. PubMed ID: 22686715
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of a combined camp approach for vector control together with active case detection of visceral leishmaniasis, post kala-azar dermal leishmaniasis, tuberculosis, leprosy and malaria in Bangladesh, India and Nepal: an exploratory study.
Banjara MR; Kroeger A; Huda MM; Kumar V; Gurung CK; Das ML; Rijal S; Das P; Mondal D
Trans R Soc Trop Med Hyg; 2015 Jun; 109(6):408-15. PubMed ID: 25918216
[TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of Parasite Kinetics in Indian Post-Kala-azar Dermal Leishmaniasis.
Moulik S; Chaudhuri SJ; Sardar B; Ghosh M; Saha B; Das NK; Chatterjee M
Clin Infect Dis; 2018 Jan; 66(3):404-410. PubMed ID: 29020350
[TBL] [Abstract][Full Text] [Related]
15. Active case detection in national visceral leishmaniasis elimination programs in Bangladesh, India, and Nepal: feasibility, performance and costs.
Huda MM; Hirve S; Siddiqui NA; Malaviya P; Banjara MR; Das P; Kansal S; Gurung CK; Naznin E; Rijal S; Arana B; Kroeger A; Mondal D
BMC Public Health; 2012 Nov; 12():1001. PubMed ID: 23164318
[TBL] [Abstract][Full Text] [Related]
16. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
17. Towards a Sustainable Vector-Control Strategy in the Post Kala-Azar Elimination Era.
Garlapati R; Iniguez E; Serafim TD; Mishra PK; Rooj B; Sinha B; Valenzuela JG; Srikantiah S; Bern C; Kamhawi S
Front Cell Infect Microbiol; 2021; 11():641632. PubMed ID: 33768013
[TBL] [Abstract][Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
[TBL] [Abstract][Full Text] [Related]
19. How do health care providers deal with kala-azar in the Indian subcontinent?
Kumar N; Singh SP; Mondal D; Joshi A; Das P; Sundar S; Kroeger A; Hirve S; Siddiqui NA; Boelaert M
Indian J Med Res; 2011 Sep; 134(3):349-55. PubMed ID: 21985818
[TBL] [Abstract][Full Text] [Related]
20. A new strategy for elimination of kala-azar from rural Bihar.
Thakur CP
Indian J Med Res; 2007 Nov; 126(5):447-51. PubMed ID: 18160749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
